The Scientific Advisory Team at Ambagon Therapeutics provides expert guidance on the development and optimization of small molecule cancer drugs. Leveraging their extensive knowledge in computational chemistry and oncology, the team advises on experimental design, molecular interactions, and the strategic direction of the company's research initiatives to stabilize oncogenic protein interactions with 14-3-3 adaptor proteins.
View all